BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo matching with BMS-986020
Drug: BMS-986020

First Posted Date: 2013-01-11

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 325

Registration Number: NCT01766817

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Cleveland Clinic Florida- Weston Hospital, Weston, Florida, United States
🇵🇪
Local Institution, Lima, Peru

and more 50 locations

Abatacept Post-marketing Clinical Study in Japan

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Abatacept
Drug: Placebo matching with Abatacept
Drug: Methotrexate

First Posted Date: 2013-01-01

Last Posted Date: 2017-05-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 405

Registration Number: NCT01758198

Locations: 🇯🇵
Local Institution, Yotsukaido, Japan
🇯🇵
Local institution, Yokohama, Japan

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Biological: Peginterferon Lambda-1a
Biological: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2012-12-21

Last Posted Date: 2015-01-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT01754974

Locations: 🇲🇽
Local Institution, Distrito Federal, Mexico

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Phase 2

Terminated

Conditions: Diabetic Kidney Disease

Interventions: Drug: Placebo matching with BMS-813160
Drug: BMS-813160

First Posted Date: 2012-12-19

Last Posted Date: 2019-07-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 319

Registration Number: NCT01752985

Locations: 🇺🇸
Academic Medical Research Institute, Los Angeles, California, United States
🇨🇦
Recherche Gcp Research, Montreal, Quebec, Canada
🇨🇦
Eastern Health Sciences Center, St. John's, Newfoundland and Labrador, Canada

and more 47 locations

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Phase 1

Completed

Conditions: CANCER, NOS

Interventions: Drug: Lirilumab
Drug: Ipilimumab

First Posted Date: 2012-12-17

Last Posted Date: 2015-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT01750580

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
University Of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Memorial Sloan Kettering Cancer Ctr, New York, New York, United States

and more 3 locations

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Biological: Pegylated-Interferon-lambda
Drug: Ribavirin
Drug: Daclatasvir

First Posted Date: 2012-12-05

Last Posted Date: 2020-08-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 71

Registration Number: NCT01741545

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Hospital Of The University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Stanford Boswell Clinic, Palo Alto, California, United States

and more 2 locations

A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Completed

Conditions: Healthy
Hepatitis C

Interventions: Drug: Placebo matching BMS-986094/INX-08189
Drug: BMS-986094/INX-08189

First Posted Date: 2012-11-26

Last Posted Date: 2014-08-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT01732848

Locations: 🇵🇷
Local Institution, San Juan, Puerto Rico
🇺🇸
New Orleans Center For Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸
Prism Research, St. Paul, Minnesota, United States

Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China

Completed

Conditions: Chronic Hepatitis B

First Posted Date: 2012-11-15

Last Posted Date: 2020-07-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3434

Registration Number: NCT01726439

Locations: 🇨🇳
Local institution, Hangzhou, Zhejiang, China
🇨🇳
Local Institution, Ningbo, Zhejiang, China
🇨🇳
Local Instution, Fushun, Liaoning, China

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Phase 2

Completed

Conditions: Squamous Cell Non-small Cell Lung Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2012-11-06

Last Posted Date: 2022-06-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 117

Registration Number: NCT01721759

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Winship Cancer Institute., Atlanta, Georgia, United States
🇺🇸
Providence Cancer Institute, Southfield, Michigan, United States

and more 17 locations

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: BMS-936558 (Nivolumab)
Biological: Placebo matching BMS-936558 (Nivolumab)
Drug: Placebo matching Dacarbazine
Drug: Dacarbazine

First Posted Date: 2012-11-06

Last Posted Date: 2022-07-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 418

Registration Number: NCT01721772

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇫🇷
Local Institution - 0013, Villejuif, France
🇫🇮
Local Institution - 0035, Helsinki, Finland

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy